(This story is for CNBC Pro subscribers only.)
Amid a vaccine-driven rebound in stocks, Goldman Sachs said these shares can lead the charge thanks to their potential for a rebound in cash flow in 2021.
"With investor attention centered around macro recovery and the recent rotation into value, we look at both of these through a cash flow lens. We focus on the trajectory of free cash flow, factoring in both financial profitability (Margin) and valuation (Yield)," Goldman Sachs analyst Deep Mehta said in a note to clients.
To capitalize on this, Goldman is focusing on equities that its analysts expect will turn cash flow profitable in 2021or recover from a recent cash flow downturn.
Free cash flow is net income minus capital expenditures, which amounts to what's left over to spend on growing the business or returning money to shareholders. This money can be used for acquisitions, paying off debt or reinvestment.
Goldman Sachs screened for stocks that are well-positioned for a positive cash flow inflection in 2021, which should drive the companies' stocks, they believe. The firm made a list of buy-rated stocks with negative free cash flow in 2020 that are expected to inflect high in 2021 and 2022.
"While some stocks on the list are ramping towards achieving cash flow profitability, others are recovering from a cash flow downturn in 2020," Mehta told clients.
Take a look at Goldman's list here.